UAMC-3203 | CAS# 2271358-64-4 | Ferroptosis inhibitor

MedKoo Cat#: 574229 | Name: UAMC-3203

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UAMC-3203 is an inhibitor of ferroptosis for inhibition of erastin-induced ferroptosis in IMR-32 neuroblastoma cells. It decreases iron-induced plasma lactate dehydrogenase (LDH) levels in a mouse model of acute iron poisoning when administered at a dose of 20 µmol/kg. It is not toxic to mice following chronic administration of a 20 µmol/kg dose for four weeks. UAMC-3203 has increased solubility and a longer half-life in mouse, rat, and human microsomes and isolated plasma than the ferroptosis inhibitor ferrostatin-1. In an in silico membrane dynamics study, UAMC-3203 was incorporated into a phospholipid bilayer.

Chemical Structure

UAMC-3203

CAS#2271358-64-4 (free base)

Theoretical Analysis

MedKoo Cat#: 574229

Name: UAMC-3203

CAS#: 2271358-64-4 (free base)

Chemical Formula: C25H37N5O2S

Exact Mass: 471.2668

Molecular Weight: 471.66

Elemental Analysis: C, 63.66; H, 7.91; N, 14.85; O, 6.78; S, 6.80

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks
100mg	USD 1,250.00	2 Weeks
200mg	USD 2,050.00	2 Weeks
500mg	USD 3,650.00	2 Weeks
1g	USD 4,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2271358-65-5 (HCl) 2271358-64-4 (free base)

Synonym

UAMC-3203; UAMC 3203; UAMC3203; UAMC-3203 free base;

IUPAC/Chemical Name

4-(cyclohexylamino)-3-[(phenylmethyl)amino]-N-[2-(1-piperazinyl)ethyl]-benzenesulfonamide

InChi Key

HSYSVXKJIVUNBR-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H37N5O2S/c31-33(32,28-15-18-30-16-13-26-14-17-30)23-11-12-24(29-22-9-5-2-6-10-22)25(19-23)27-20-21-7-3-1-4-8-21/h1,3-4,7-8,11-12,19,22,26-29H,2,5-6,9-10,13-18,20H2

SMILES Code

O=S(C(C=C1NCC2=CC=CC=C2)=CC=C1NC3CCCCC3)(NCCN4CCNCC4)=O

Appearance

A solution in ethanol

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 471.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kan S, Feng S, Zhao X, Chen Z, Zhou M, Liu L, Zhu H, Cheng Y, Fu X, Hu W, Zhu R. Author Correction: UAMC-3203 inhibits ferroptosis and promotes functional recovery in rats with spinal cord injury. Sci Rep. 2024 Nov 14;14(1):28060. doi: 10.1038/s41598-024-78546-5. Erratum for: Sci Rep. 2024 Aug 30;14(1):20180. doi: 10.1038/s41598-024-70926-1. PMID: 39543269; PMCID: PMC11564897. 2: Kan S, Feng S, Zhao X, Chen Z, Zhou M, Liu L, Zhu H, Cheng Y, Fu X, Hu W, Zhu R. UAMC-3203 inhibits ferroptosis and promotes functional recovery in rats with spinal cord injury. Sci Rep. 2024 Aug 30;14(1):20180. doi: 10.1038/s41598-024-70926-1. Erratum in: Sci Rep. 2024 Nov 14;14(1):28060. doi: 10.1038/s41598-024-78546-5. PMID: 39215144; PMCID: PMC11364804. 3: Adelusi OB, Etemadi Y, Akakpo JY, Ramachandran A, Jaeschke H. Effect of ferroptosis inhibitors in a murine model of acetaminophen-induced liver injury. J Biochem Mol Toxicol. 2024 Aug;38(8):e23791. doi: 10.1002/jbt.23791. PMID: 39082238; PMCID: PMC11382325. 4: Peleman C, Hellemans S, Veeckmans G, Arras W, Zheng H, Koeken I, Van San E, Hassannia B, Walravens M, Kayirangwa E, Beyene NT, Van Herck MA, De Vos WH, Pintelon I, van Nassauw L, Oosterlinck B, Smet A, Vits L, Dirinck E, Verrijken A, De Man J, Van Eyck A, Kwanten WJ, Vonghia L, Driessen A, Augustyns K, Toyokuni S, De Winter B, Van Steenkiste C, Francque S, Vanden Berghe T. Ferroptosis is a targetable detrimental factor in metabolic dysfunction- associated steatotic liver disease. Cell Death Differ. 2024 Sep;31(9):1113-1126. doi: 10.1038/s41418-024-01348-9. Epub 2024 Jul 26. PMID: 39060422; PMCID: PMC11369286. 5: Ryan F, Blex C, Ngo TD, Kopp MA, Michalke B, Venkataramani V, Curran L, Schwab JM, Ruprecht K, Otto C, Jhelum P, Kroner A, David S. Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury. Acta Neuropathol. 2024 Jun 22;147(1):106. doi: 10.1007/s00401-024-02758-2. PMID: 38907771; PMCID: PMC11193702. 6: Horinouchi T, Mazaki Y, Miwa S. Mechanism of cytotoxicity induced by the cigarette smoke extract (CSE) of heated tobacco products in vascular smooth muscle cells: A comparative study of the cytotoxic effects of CSE and the ferroptosis inducer, erastin. J Pharmacol Sci. 2024 Feb;154(2):86-96. doi: 10.1016/j.jphs.2023.12.010. Epub 2023 Dec 27. PMID: 38246732. 7: Van San E, Debruyne AC, Veeckmans G, Tyurina YY, Tyurin VA, Zheng H, Choi SM, Augustyns K, van Loo G, Michalke B, Venkataramani V, Toyokuni S, Bayir H, Vandenabeele P, Hassannia B, Vanden Berghe T. Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression. Cell Death Differ. 2023 Sep;30(9):2092-2103. doi: 10.1038/s41418-023-01195-0. Epub 2023 Aug 4. PMID: 37542104; PMCID: PMC10482919. 8: Puylaert P, Roth L, Van Praet M, Pintelon I, Dumitrascu C, van Nuijs A, Klejborowska G, Guns PJ, Berghe TV, Augustyns K, De Meyer GRY, Martinet W. Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques. Angiogenesis. 2023 Nov;26(4):505-522. doi: 10.1007/s10456-023-09877-6. Epub 2023 Apr 29. PMID: 37120604; PMCID: PMC10542744. 9: Balla A, Tran B, Valtari A, Steven P, Scarpellini C, Augustyns K, Urtti A, Vellonen KS, Ruponen M. A Novel Ferroptosis Inhibitor UAMC-3203, a Potential Treatment for Corneal Epithelial Wound. Pharmaceutics. 2022 Dec 29;15(1):118. doi: 10.3390/pharmaceutics15010118. PMID: 36678747; PMCID: PMC9863691. 10: Zhao YY, Yang YQ, Sheng HH, Tang Q, Han L, Wang SM, Wu WY. GPX4 Plays a Crucial Role in Fuzheng Kang'ai Decoction-Induced Non-Small Cell Lung Cancer Cell Ferroptosis. Front Pharmacol. 2022 Apr 13;13:851680. doi: 10.3389/fphar.2022.851680. PMID: 35496303; PMCID: PMC9043103. 11: Jin T, He Q, Cheng C, Li H, Liang L, Zhang G, Su C, Xiao Y, Bradley J, Peberdy MA, Ornato JP, Tang W. UAMC-3203 or/and Deferoxamine Improve Post- Resuscitation Myocardial Dysfunction Through Suppressing Ferroptosis in a Rat Model of Cardiac Arrest. Shock. 2022 Mar 1;57(3):344-350. doi: 10.1097/SHK.0000000000001869. PMID: 34618729; PMCID: PMC8868183. 12: Devisscher L, Van Coillie S, Hofmans S, Van Rompaey D, Goossens K, Meul E, Maes L, De Winter H, Van Der Veken P, Vandenabeele P, Berghe TV, Augustyns K. Discovery of Novel, Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. J Med Chem. 2018 Nov 21;61(22):10126-10140. doi: 10.1021/acs.jmedchem.8b01299. Epub 2018 Nov 6. PMID: 30354101.